CR11486A - Tratamiento de cancer uterino y cancer de ovario con un inhibidor de parp solo o en combinacion con agentes anti-tumorales - Google Patents

Tratamiento de cancer uterino y cancer de ovario con un inhibidor de parp solo o en combinacion con agentes anti-tumorales

Info

Publication number
CR11486A
CR11486A CR11486A CR11486A CR11486A CR 11486 A CR11486 A CR 11486A CR 11486 A CR11486 A CR 11486A CR 11486 A CR11486 A CR 11486A CR 11486 A CR11486 A CR 11486A
Authority
CR
Costa Rica
Prior art keywords
cancer
ovario
treatment
combination
parp inhibitor
Prior art date
Application number
CR11486A
Other languages
English (en)
Inventor
Valeria Ossovskaya
Barry Sherman
Charles Bradley
Original Assignee
Bipar Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40623903&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR11486(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bipar Sciences Inc filed Critical Bipar Sciences Inc
Publication of CR11486A publication Critical patent/CR11486A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/212IFN-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/215IFN-beta
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/217IFN-gamma
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporciona un método de tratamiento de cáncer de útero o cáncer de ovario en un paciente, que comprende administrar al paciente al menos un inhibidor de PARP.
CR11486A 2007-11-12 2010-06-10 Tratamiento de cancer uterino y cancer de ovario con un inhibidor de parp solo o en combinacion con agentes anti-tumorales CR11486A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US98733507P 2007-11-12 2007-11-12
US1236407P 2007-12-07 2007-12-07
US5852808P 2008-06-03 2008-06-03
PCT/US2008/012757 WO2009064444A2 (en) 2007-11-12 2008-11-12 Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents

Publications (1)

Publication Number Publication Date
CR11486A true CR11486A (es) 2013-08-09

Family

ID=40623903

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11486A CR11486A (es) 2007-11-12 2010-06-10 Tratamiento de cancer uterino y cancer de ovario con un inhibidor de parp solo o en combinacion con agentes anti-tumorales

Country Status (20)

Country Link
US (2) US20090123419A1 (es)
EP (1) EP2217244A4 (es)
JP (1) JP2011503071A (es)
KR (1) KR20100102607A (es)
CN (1) CN101918003A (es)
AU (1) AU2008321382A1 (es)
CA (1) CA2705417A1 (es)
CO (1) CO6290649A2 (es)
CR (1) CR11486A (es)
DO (2) DOP2010000142A (es)
EC (1) ECSP10010235A (es)
GT (1) GT201000137A (es)
IL (1) IL205633A0 (es)
MA (1) MA32748B1 (es)
MX (1) MX2010005221A (es)
NI (1) NI201000084A (es)
NZ (1) NZ586123A (es)
SG (1) SG185954A1 (es)
TN (1) TN2010000209A1 (es)
WO (1) WO2009064444A2 (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG164368A1 (en) * 2005-07-18 2010-09-29 Bipar Sciences Inc Treatment of cancer
AU2007354301A1 (en) * 2006-06-12 2008-12-04 Bipar Sciences, Inc. Method of treating diseases with PARP inhibitors
US20100279327A1 (en) * 2006-06-12 2010-11-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
US20100160442A1 (en) * 2006-07-18 2010-06-24 Ossovskaya Valeria S Formulations for cancer treatment
US7538252B2 (en) * 2006-09-05 2009-05-26 Bipar Sciences, Inc. Drug design for tubulin inhibitors, compositions, and methods of treatment thereof
AU2007292306A1 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Inhibition of fatty acid synthesis by PARP inhibitors and methods of treatment thereof
EP2059498A4 (en) * 2006-09-05 2011-01-12 Bipar Sciences Inc TREATMENT OF CANCER
EP2059802A4 (en) * 2006-09-05 2010-09-08 Bipar Sciences Inc METHODS FOR DESIGNING PARP INHIBITORS AND USES THEREOF
NZ586123A (en) * 2007-11-12 2012-12-21 Bipar Sciences Inc Treatment of ovarian cancer with 4-iodo-3-nitrobenzamide in combination with topoisomerase inhibitors
AU2008321128A1 (en) * 2007-11-12 2009-05-22 Bipar Sciences, Inc. Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents
RU2010128107A (ru) * 2007-12-07 2012-01-20 Байпар Сайенсиз, Инк. (Us) Лечение рака ингибиторами топоизомеразы в комбинации с ингибиторами parp
WO2011060380A1 (en) * 2009-11-14 2011-05-19 The Regents Of The University Of California Pik3ca mutation status and sash1 expression predicts synergy between lapatinib and an akt inhibitor in her2 positive breast cancer
US20130345164A1 (en) * 2010-04-21 2013-12-26 University Of Medicine And Dentistry Of New Jersey Treatments for cellular proliferative disorders and identification thereof
WO2011153383A1 (en) * 2010-06-04 2011-12-08 Bipar Science, Inc. Methods of treating platinum-resistant recurrent ovarian cancer with 4-iodo-3-nitrobenzamide in combination with an anti-metabolite and a platinum compound
WO2011153382A1 (en) * 2010-06-04 2011-12-08 Bipar Sciences, Inc. Methods of treating platinum-sensitive recurrent ovarian cancer with 4-iodo-3-nitrobenzamide in combination with an anti-metabolite and platinum compound
JP2013531069A (ja) * 2010-07-19 2013-08-01 バイパー サイエンシズ,インコーポレイティド 4−ヨード−3−ニトロベンズアミド及びイリノテカンを用いる転移性乳癌の治療方法
EP2636667B1 (en) * 2010-11-05 2019-01-09 Zhejiang Hisun Pharmaceutical Co. Ltd. Benzamide derivative with anticancer activity and preparation method and use thereof
US20140296281A1 (en) * 2011-11-25 2014-10-02 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for screening a brca1 loss-of-function in a subject suffering from a cancer
FR2984750B1 (fr) * 2011-12-23 2014-01-10 Lfb Biotechnologies Nouvelles compositions pharmaceutiques comprenant un anticorps liant le recepteur humain de l'hormone anti-mullerienne de type ii
WO2013123236A1 (en) * 2012-02-14 2013-08-22 Purdue Pharma L.P. Systems and methods to quantify analytes in keratinized samples
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
TWI444358B (zh) * 2012-07-09 2014-07-11 Univ Chang Gung 一種含有5-硝基苯之衍生物,透過抑制腫瘤細胞誘發血小板凝集反應作為癌症轉移治療方式
US20140186293A1 (en) * 2012-12-31 2014-07-03 University Of Louisville Research Foundation, Inc. Immunoglobulin-bound extracellular vesicles and uses thereof
RS57900B1 (sr) 2013-03-15 2019-01-31 Truckee Applied Genomics Llc Postupci i reagensi za održavanje u životu ćelija kancera u hirurški uklonjenom tkivu
MX2016013027A (es) 2014-04-04 2017-05-23 Del Mar Pharmaceuticals Uso de dianhidrogalactitol y analogos o derivados del mismo para tratar cancer de celulas no pequeñas del pulmon y cancer de ovario.
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
CN114927178A (zh) * 2015-06-12 2022-08-19 格尼亚Ip控股私人有限公司 患者和生物样本识别和追踪的方法和系统
KR20180037210A (ko) 2015-08-20 2018-04-11 입센 바이오팜 리미티드 암 치료를 위한 리포좀 이리노테칸 및 parp 저해제를 이용하는 조합요법
WO2017034957A1 (en) 2015-08-21 2017-03-02 Merrimack Pharmaceuticals, Inc. Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin
CN108697666A (zh) 2016-02-29 2018-10-23 辛塔制药公司 用于治疗卵巢癌的组合疗法
HRP20240136T1 (hr) * 2016-06-29 2024-04-12 Tesaro, Inc. Metode liječenja raka jajnika
TWI806840B (zh) * 2016-09-27 2023-07-01 英屬開曼群島商百濟神州有限公司 使用包含parp抑制劑的組合產品治療癌症
MA46709A (fr) 2016-11-02 2019-09-11 Ipsen Biopharm Ltd Traitement du cancer gastrique au moyen de polythérapies comprenant de l'oxaliplatine, du 5-fluoruracile (et de la leucovorine) et de l'irinotécan sous forme liposomale
KR20190111116A (ko) * 2017-02-06 2019-10-01 시티 오브 호프 암의 치료
WO2018160758A1 (en) * 2017-02-28 2018-09-07 Bacha Jeffrey A Use of dianhydrogalactitol or analogs and derivatives in combination with a p53 modulator or a parp inhibitor
US11622961B2 (en) 2017-05-18 2023-04-11 Tesaro, Inc. Combination therapies for treating cancer
WO2018237327A1 (en) 2017-06-22 2018-12-27 Triact Therapeutics, Inc. METHODS OF TREATING GLIOBLASTOMA
US20200121703A1 (en) * 2017-06-26 2020-04-23 The Cleveland Clinic Foundation Cancer treatment
US11628144B2 (en) 2017-09-29 2023-04-18 Triact Therapeutics, Inc. Iniparib formulations and uses thereof
JP2020536066A (ja) 2017-09-30 2020-12-10 テサロ, インコーポレイテッド 癌を治療するための併用療法
JP6915865B2 (ja) * 2017-10-03 2021-08-04 学校法人 愛知医科大学 No産生抑制剤及び固形腫瘍に対する転移・浸潤抑制剤
EA202090655A1 (ru) * 2017-10-06 2020-12-07 Тесаро, Инк. Комбинированные терапевтические средства и их применение
JP7372253B2 (ja) 2018-04-05 2023-10-31 ノビガ・リサーチ・エービー 癌の治療における使用のためのチューブリン重合阻害剤とポリ(adp-リボース)ポリメラーゼ(parp)阻害剤との新規組合せ
EP3927841A1 (en) * 2019-02-21 2021-12-29 F. Hoffmann-La Roche AG Improved nucleic acid target enrichment and related methods
US11704494B2 (en) 2019-05-31 2023-07-18 Ab Initio Technology Llc Discovering a semantic meaning of data fields from profile data of the data fields
CN110600098A (zh) * 2019-08-09 2019-12-20 广州中医药大学第一附属医院 一种临床化学自动审核方法、系统、装置和存储介质
CN112316149A (zh) * 2020-11-11 2021-02-05 王海涛 一种治疗tp53突变的晚期难治性实体瘤的药物及应用
WO2024108231A1 (en) * 2022-11-18 2024-05-23 University Of South Florida Physiological modeling of multiphase intra-arterial ct angiography for hepatic embolization therapy

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2669583A (en) * 1954-02-16 X-amroo-zralkoxbbenzamdjes
US2006735A (en) * 1932-11-17 1935-07-02 Gen Aniline Works Inc Nitro-aryl amino-aryl amines
NL247377A (es) * 1957-11-25
US3228833A (en) * 1962-12-17 1966-01-11 Sterling Drug Inc Anticoccidial compositions and methods of using same
US4526988A (en) * 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
US5215738A (en) * 1985-05-03 1993-06-01 Sri International Benzamide and nicotinamide radiosensitizers
US5032617A (en) * 1985-05-03 1991-07-16 Sri International Substituted benzamide radiosensitizers
US6407079B1 (en) * 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
EP0229674B1 (en) * 1986-01-17 1994-06-22 Preventive Medicine Institute Test to determine predisposition or susceptibility to DNA associated diseases
US5283352A (en) * 1986-11-28 1994-02-01 Orion-Yhtyma Oy Pharmacologically active compounds, methods for the preparation thereof and compositions containing the same
US5223608A (en) * 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US5177075A (en) * 1988-08-19 1993-01-05 Warner-Lambert Company Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process
US5719151A (en) * 1990-05-04 1998-02-17 Shall; Sydney Substituted benzene compounds
US5633282A (en) * 1990-05-25 1997-05-27 British Technology Group Limited Inhibition of viral infection
US5631038A (en) * 1990-06-01 1997-05-20 Bioresearch, Inc. Specific eatable taste modifiers
US5637618A (en) * 1990-06-01 1997-06-10 Bioresearch, Inc. Specific eatable taste modifiers
SK283693B6 (sk) * 1990-09-28 2003-12-02 Smithkline Beecham Corporation Spôsob prípravy kamptotecínu alebo jeho farmaceuticky prijateľnej soli
US5484951A (en) * 1990-10-19 1996-01-16 Octamer, Incorporated 5-iodo-6-amino-6-nitroso-1,2-benzopyrones useful as cytostatic and antiviral agents
US5191082A (en) * 1990-12-20 1993-03-02 North Carolina State University Camptothecin intermediate and method of making camptothecin intermediates
US5162532A (en) * 1990-12-20 1992-11-10 North Carolina State University Intermediates and method of making camptothecin and camptothecin analogs
US5200524A (en) * 1990-12-20 1993-04-06 North Carolina State University Camptothecin intermediates and method of making same
US5753674A (en) * 1991-10-22 1998-05-19 Octamer, Inc. Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as retroviral inactivating agents, anti-retroviral agents, anti-retroviral agents and anti-tumor agents
US5482975A (en) * 1991-10-22 1996-01-09 Octamer, Inc. Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as retroviral inactivating agents, anti-retroviral agents and anti-tumor agents
US5464871A (en) * 1993-05-12 1995-11-07 Octamer, Inc. Aromatic nitro and nitroso compounds and their metabolites useful as anti-viral and anti-tumor agents
US5516941A (en) * 1991-10-22 1996-05-14 Octamer, Inc. Specific inactivators of "retroviral" (asymmetric) zinc fingers
US5877185A (en) * 1991-10-22 1999-03-02 Octamer, Inc. Synergistic compositions useful as anti-tumor agents
US5783599A (en) * 1993-02-24 1998-07-21 Octamer Inc Methods of treating cancer and viral infections with 5-iodo-6-amino-and 5-iodo-6-nitroso-1 2-benzopyrones
JP3025602B2 (ja) * 1993-05-21 2000-03-27 デビオファーム エス.アー. 光学的に高純度なシス−オキザラート(トランス−l−1,2−シクロヘキサンジアミン)白金(II)錯体の製造方法
US6015792A (en) * 1993-05-26 2000-01-18 Bioresearch, Inc. Specific eatable taste modifiers
GB9404485D0 (en) * 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
US5589483A (en) * 1994-12-21 1996-12-31 Geron Corporation Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5736576A (en) * 1996-06-04 1998-04-07 Octamer, Inc. Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity
US6017958A (en) * 1996-06-04 2000-01-25 Octamer, Inc. Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity
JP2001518935A (ja) * 1997-03-26 2001-10-16 バイオソース テクノロジーズ,インコーポレイティド 抗癌剤としてのジ―アリールエーテル類及びそれらの誘導体
US5908861A (en) * 1997-05-13 1999-06-01 Octamer, Inc. Methods for treating inflammation and inflammatory disease using pADPRT inhibitors
US6235748B1 (en) * 1997-09-03 2001-05-22 Guilford Pharmaceuticals Inc. Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
US6514983B1 (en) * 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
US6380193B1 (en) * 1998-05-15 2002-04-30 Guilford Pharmaceuticals Inc. Fused tricyclic compounds, methods and compositions for inhibiting PARP activity
US6395749B1 (en) * 1998-05-15 2002-05-28 Guilford Pharmaceuticals Inc. Carboxamide compounds, methods, and compositions for inhibiting PARP activity
IL143303A0 (en) * 1998-11-27 2002-04-21 Basf Ag Substituted benzimidazoles and their use as parp inhibitors
US6387902B1 (en) * 1998-12-31 2002-05-14 Guilford Pharmaceuticals, Inc. Phenazine compounds, methods and pharmaceutical compositions for inhibiting PARP
US6201020B1 (en) * 1998-12-31 2001-03-13 Guilford Pharmaceuticals, Inc. Ortho-diphenol compounds, methods and pharmaceutical compositions for inhibiting parp
EP1148053A4 (en) * 1999-01-26 2002-03-06 Ono Pharmaceutical Co 2H-PHTHALAZIN-1-ON DERIVATIVES AND DRUG COMPOSITIONS THAT CONTAIN THESE DERIVATIVES AS ACTIVE INGREDIENTS
DE19921567A1 (de) * 1999-05-11 2000-11-16 Basf Ag Verwendung von Phthalazine-Derivaten
ECSP003637A (es) * 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
US7122679B2 (en) * 2000-05-09 2006-10-17 Cephalon, Inc. Multicyclic compounds and the use thereof
US6723733B2 (en) * 2000-05-19 2004-04-20 Guilford Pharmaceuticals, Inc. Sulfonamide and carbamide derivatives of 6(5H)phenanthridinones and their uses
ITMI20002358A1 (it) * 2000-10-31 2002-05-01 Flavio Moroni Derivati di tieno ,2, 3-c|isochinolin-3-one come inibitori della poli(a dp-ribosio)polimerasi
AUPR201600A0 (en) * 2000-12-11 2001-01-11 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivative
US20050113283A1 (en) * 2002-01-18 2005-05-26 David Solow-Cordero Methods of treating conditions associated with an EDG-4 receptor
AUPS019702A0 (en) * 2002-01-29 2002-02-21 Fujisawa Pharmaceutical Co., Ltd. Condensed heterocyclic compounds
US20040034078A1 (en) * 2002-06-14 2004-02-19 Agouron Pharmaceuticals, Inc. Benzimidazole inhibitors of poly(ADP-ribosyl) polymerase
JP2006508126A (ja) * 2002-11-06 2006-03-09 アザヤ セラピューティクス インコーポレイティッド 薬学的製剤のタンパク質安定化されたリポソーム製剤
WO2005016970A2 (en) * 2003-05-01 2005-02-24 Imclone Systems Incorporated Fully human antibodies directed against the human insulin-like growth factor-1 receptor
MXPA05012812A (es) * 2003-05-28 2006-02-28 Guilford Pharm Inc Compuestos, metodos y composiciones farmaceuticas para inhibir poli(adenosina-5'-difosfo-ribosa)polimerasa(parp).
CA2533332C (en) * 2003-07-25 2012-01-10 Cancer Research Technology Limited Therapeutic compounds
AU2004266572A1 (en) * 2003-08-01 2005-03-03 Wyeth Holdings Corporation Use of combination of an epidermal growth factor receptor kinase inhibitor and cytotoxic agents for treatment and inhibition of cancer
MXPA06002499A (es) * 2003-09-04 2006-06-20 Aventis Pharma Inc Indoles sustituidos como inhibidores de poli (adp-ribosa) polimerasa (parp).
WO2005023765A1 (en) * 2003-09-11 2005-03-17 Pharmacia & Upjohn Company Llc Method for catalyzing amidation reactions by the presence of co2
GB0419072D0 (en) * 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
JP2008513435A (ja) * 2004-09-22 2008-05-01 ファイザー・インク ポリ(adp−リボース)ポリメラーゼ阻害剤を含む治療用組成物
MX2007002461A (es) * 2004-09-22 2008-03-13 Pfizer Formas polimorficas y amorfas de la sal fosfato de 8-fluoro-2-{4-[metilamino)metil]fenil}-1, 3, 4, 5-tetrahidro-6h-azepino [5, 4, 3-cd]indol-6-ona.
US20060094676A1 (en) * 2004-10-29 2006-05-04 Ronit Lahav Compositions and methods for treating cancer using compositions comprising an inhibitor of endothelin receptor activity
AU2006257815A1 (en) * 2005-06-10 2006-12-21 Bipar Sciences, Inc. PARP modulators and treatment of cancer
SG164368A1 (en) * 2005-07-18 2010-09-29 Bipar Sciences Inc Treatment of cancer
DE102006037399A1 (de) * 2006-08-10 2008-02-14 Archimica Gmbh Verfahren zur Herstellung von Arylaminen
US7538252B2 (en) * 2006-09-05 2009-05-26 Bipar Sciences, Inc. Drug design for tubulin inhibitors, compositions, and methods of treatment thereof
EP2059498A4 (en) * 2006-09-05 2011-01-12 Bipar Sciences Inc TREATMENT OF CANCER
AU2007292306A1 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Inhibition of fatty acid synthesis by PARP inhibitors and methods of treatment thereof
EP2059802A4 (en) * 2006-09-05 2010-09-08 Bipar Sciences Inc METHODS FOR DESIGNING PARP INHIBITORS AND USES THEREOF
JP2011500684A (ja) * 2007-10-19 2011-01-06 バイパー サイエンシズ,インコーポレイティド ベンゾピロン系parp阻害剤を用いる癌の処置方法および組成物
AU2008321128A1 (en) * 2007-11-12 2009-05-22 Bipar Sciences, Inc. Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents
NZ586123A (en) * 2007-11-12 2012-12-21 Bipar Sciences Inc Treatment of ovarian cancer with 4-iodo-3-nitrobenzamide in combination with topoisomerase inhibitors
RU2010128107A (ru) * 2007-12-07 2012-01-20 Байпар Сайенсиз, Инк. (Us) Лечение рака ингибиторами топоизомеразы в комбинации с ингибиторами parp

Also Published As

Publication number Publication date
NZ586123A (en) 2012-12-21
ECSP10010235A (es) 2010-07-30
KR20100102607A (ko) 2010-09-24
MX2010005221A (es) 2010-09-28
JP2011503071A (ja) 2011-01-27
EP2217244A2 (en) 2010-08-18
DOP2010000142A (es) 2010-07-31
DOP2012000290A (es) 2013-03-31
WO2009064444A2 (en) 2009-05-22
WO2009064444A9 (en) 2009-07-02
AU2008321382A1 (en) 2009-05-22
EP2217244A4 (en) 2011-08-31
SG185954A1 (en) 2012-12-28
US20100009930A1 (en) 2010-01-14
MA32748B1 (fr) 2011-11-01
NI201000084A (es) 2011-04-27
TN2010000209A1 (en) 2011-11-11
IL205633A0 (en) 2010-11-30
US20090123419A1 (en) 2009-05-14
CO6290649A2 (es) 2011-06-20
CN101918003A (zh) 2010-12-15
GT201000137A (es) 2012-04-23
CA2705417A1 (en) 2009-05-22

Similar Documents

Publication Publication Date Title
CR11486A (es) Tratamiento de cancer uterino y cancer de ovario con un inhibidor de parp solo o en combinacion con agentes anti-tumorales
TN2010000208A1 (en) Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents
CY1110889T1 (el) C-αρυλο γλυκοζιτικοι sglt2 αναστολεις και μεθοδος για την παραγωγη τους
EP1962839A4 (en) ADMINISTRATION OF A MNTOR INHIBITOR FOR THE TREATMENT OF PATIENTS WITH CANCER
TW200738262A (en) Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
EP1876893A4 (en) TREATMENT OF CANCER BY THE COMBINED INHIBITION OF PROTEASOME AND TELOMERASE ACTIVITIES
MX2010006991A (es) Tratamientos de cancer terapeuticos.
GT200600092A (es) Alargar el tiempo hasta la progresion de la enfermedad o la supervivencia de los pacientes de cancer
MX2011008221A (es) Tratamiento de cancer de pulmon con un compuesto de nitrobenzamida en combinacion con un inhibidor de un factor de crecimieno.
MY160041A (en) Compositions and methods for treating parasitic infections
TR201708567T4 (tr) Sigma ligandların kemik kanseri ağrısında kullanımı.
BRPI0908635B8 (pt) composto e/ou um sal farmaceuticamente aceitável do mesmo e composição farmacêutica
UY33740A (es) Método para tratar el cáncer de mama y cáncer de ovarios
UA100702C2 (ru) Комбинационная терапия рака поджелудочной железы с использованием антигенного пептида и химиотерапевтического средства - гемцитабина
UY32546A (es) Composiciones y metodos para tratar cancer
DOP2013000131A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek
TW200603792A (en) Monotherapy for the treatment of psoriasis with cyclooxygenase-2 selective inhibitors
EA200802136A1 (ru) Лечение меланомы
NO20071330L (no) Enzyminhibitor i leukemi
MX2010002046A (es) Tratamiento de cancer de pulmon.
UA99934C2 (ru) Лечение рака молочной железы с помощью соединения 4-йодо-3-нитробензамида в комбинации с противоопухолевыми средствами
AR051035A1 (es) Uso de epotilonas en el tratamiento de metastasis en hueso
UA100869C2 (ru) Лечение рака яичника с помощью соединения йодонитробензамида в комбинации с противоопухолевыми средствами
NI201300052A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek
UA38745U (ru) Способ хирургического лечения больных раком яичника iii-iv стади